Partnership in early drug development
June 11, 2012
Roche has been boosted by the news that the US Food and Drug Administration has given the green light to Perjeta, a new personalised medicine for previously-untreated HER2-positive metastatic breast cancer
February 08, 2012
US gene specialist Illumina has rejected Roche's hostile $5.70 million takeover bid, with its board describing the offer as "grossly inadequate in multiple respects"
February 01, 2012
Roche’s 2011 earnings may have experienced a 4% drop but the company is remaining optimistic about growth in the new year as new products flood onto the market.
July 15, 2011
Roche will seek approval later this year for its investigational breast cancer drug pertuzumab, based on encouraging results of a late-stage trial
PharmaTimes 2013 Copyright | RSS Feed Subscriptions Website by DCSL Software